Tianjin TEDA Biomedical Engineering Company Limited (08189) reported that its total authorized share capital as of the end of February 2026 remained at RMB213.39 million, reflecting 1.44 billion H shares and 697.50 million domestic shares at a par value of RMB0.1 each.

During the month, the company’s issued H shares stood at 1.44 billion, while domestic shares totaled 697.50 million, with no issuance or cancellation of treasury shares. The public float requirement of a 25% minimum threshold was confirmed as satisfied. No share options, warrants, or convertible securities were outstanding throughout the period.